|
306 Companies |
|
474 Products |
|
474 Products |
|
223 Mechanisms of Action |
|
25 Trials |
|
4911 News |
|
| «12...87888990919293949596979899» |
- ||||| Pegasys (pegylated interferon ? -2a) / Roche
New P4 trial: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B. (clinicaltrials.gov) - Jan 25, 2012
P4, N=150, Completed, Sponsor: Hoffmann-La Roche
- Legalon (silibinin) / Mylan
New P2 trial: Effect of LEGALON SIL on Hepatitis C Virus Recurrence in Stable Liver Transplanted Patients (clinicaltrials.gov) - Jan 24, 2012
P2, N=44, Terminated, Sponsor: Rottapharm
- pravastatin / Generic mfg., sorafenib / Generic mfg.
Enrollment open, Metastases: Efficacy and Safety Study of Sorafenib Plus Pravastatin to Treat Advanced Hepatocarcinoma (clinicaltrials.gov) - Jan 24, 2012
P2, N=216, Recruiting, Sponsor: Hospital Donostia
Not yet recruiting --> Recruiting
- Enrollment change: Observational Study of Persons With Hepatitis B Virus Infection in North America (clinicaltrials.gov) - Jan 23, 2012
P=N/A, N=2500, Recruiting, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting --> Recruiting N=200 --> 2500
- Enrollment change: A Multi-Center Group to Study Acute Liver Failure in Children (clinicaltrials.gov) - Jan 23, 2012
P=N/A, N=300, Recruiting, Sponsor: University of Pittsburgh
N=200 --> 2500 N=1000 --> 300
- ||| Trial completion: Overcoming Psychiatric Barriers to the Treatment of Hepatitis C (clinicaltrials.gov) - Jan 23, 2012
P=N/A, N=101, Completed, Sponsor: University of North Carolina, Chapel Hill
N=1000 --> 300 Active, not recruiting --> Completed
- Enrollment change: ART and HCV: Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIV (clinicaltrials.gov) - Jan 23, 2012
P2, N=18, Completed, Sponsor: University of Cincinnati
Active, not recruiting --> Completed N=30 --> 18
- ||||| Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe, lomibuvir (VX 222) / Trek Therapeutics
New P2 trial: A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis (clinicaltrials.gov) - Jan 23, 2012
P2, N=103, Completed, Sponsor: Vertex Pharmaceuticals Incorporated
- Trial completion: ART and HCV: Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIV (clinicaltrials.gov) - Jan 23, 2012
P2, N=18, Completed, Sponsor: University of Cincinnati
N=30 --> 18 Active, not recruiting --> Completed
- | abiraterone acetate / Generic mfg.
New P1 trial: A Pharmacokinetic Study of Abiraterone Acetate in Patients With Severe Hepatic Impairment Compared to Patients With Normal Hepatic Function (clinicaltrials.gov) - Jan 22, 2012
P1, N=16, Completed, Sponsor: Janssen Research & Development, LLC
- | tenofovir disoproxil fumarate / Generic mfg.
Trial completion: Pharmacokinetic (PK) Profiles of Tenofovir Disoproxil Fumarate (TDF) 300 mg in Healthy Chinese Subjects (clinicaltrials.gov) - Jan 19, 2012
P1, N=14, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Trial completion: Post-marketing Surveillance of HIV-infected Patients With Chronic Hepatitis C Treated With PegIntron Pen and Rebetol (Study P04584) (clinicaltrials.gov) - Jan 19, 2012
P=N/A, N=232, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| New P3 trial: A Confirmatory Study of Hepabulin IV in HBsAg Positive Liver Transplantation Recipients (clinicaltrials.gov) - Jan 18, 2012
P3, N=80, Active, not recruiting, Sponsor: SK Chemicals Co.,Ltd.
- | Trial completion, Surgery: Feasibility of a Minimally Invasive Image-Guided Surgery System for Hepatic Procedures (clinicaltrials.gov) - Jan 18, 2012
P=N/A, N=20, Completed, Sponsor: Pathfinder Therapeutics
Active, not recruiting --> Completed Recruiting --> Completed
- Trial completion: The Effect of Probiotics (VSL) on Portal Hypertension (clinicaltrials.gov) - Jan 18, 2012
P1/2, N=18, Completed, Sponsor: University of Alberta
Recruiting --> Completed Recruiting --> Completed
- sorafenib / Generic mfg.
Trial initiation date: Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer (clinicaltrials.gov) - Jan 18, 2012
P2, N=20, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Initiation date: Oct 2011 --> Jan 2012
- |||||||||| Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
New P3 trial: INSIGHT: An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1) (clinicaltrials.gov) - Jan 18, 2012
P3, N=163, Active, not recruiting, Sponsor: Janssen-Cilag International NV
- pioglitazone / Generic mfg.
Trial completion: Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance (clinicaltrials.gov) - Jan 18, 2012
P2, N=19, Completed, Sponsor: AIDS Clinical Trials Group
Initiation date: Oct 2011 --> Jan 2012 Active, not recruiting --> Completed
- Selzentry (maraviroc) / ViiV Healthcare
Trial withdrawal, Combination therapy: Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients (clinicaltrials.gov) - Jan 17, 2012
P4, N=0, Withdrawn, Sponsor: ViiV Healthcare
Active, not recruiting --> Completed Terminated --> Withdrawn
- odanacatib (MK-0822) / Merck (MSD)
New P1 trial: Assessment of Pharmacokinetics of Single Dose Odanacatib (MK-0822) in Participants With Moderate Hepatic Insufficiency (MK-0822-070) (clinicaltrials.gov) - Jan 17, 2012
P1, N=16, Completed, Sponsor: Merck
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial completion: Study of 5-FU + Leucovorin + CPT-11 in Patients With Resectable Liver Metastases From Colorectal Adenocarcinoma (clinicaltrials.gov) - Jan 17, 2012
P2, N=70, Completed, Sponsor: AHS Cancer Control Alberta
Terminated --> Withdrawn Active, not recruiting --> Completed
- Enrollment change: An Integrated Care Model for Improving Hepatitis C Virus Patient Outcomes (clinicaltrials.gov) - Jan 16, 2012
P=N/A, N=448, Active, not recruiting, Sponsor: Department of Veterans Affairs
Active, not recruiting --> Completed N=360 --> 448
- ||| Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
New P1 trial: A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects (clinicaltrials.gov) - Jan 16, 2012
P1, N=64, Completed, Sponsor: Vertex Pharmaceuticals Incorporated
- | Victrelis (boceprevir) / Roche, Merck (MSD)
Trial completion: A Study to Evaluate the Pharmacokinetic Effect of SCH 503034 (Boceprevir) on Methadone or Buprenorphine/Naloxone Plasma Concentrations (P08123) (clinicaltrials.gov) - Jan 16, 2012
P1, N=21, Completed, Sponsor: Merck Sharp & Dohme Corp.
N=360 --> 448 Recruiting --> Completed
- | modafinil / Generic mfg.
Trial completion: Modafinil in the Treatment of Fatigue in Patients With Primary Biliary Cirrhosis (PBC) (clinicaltrials.gov) - Jan 16, 2012
P1, N=40, Completed, Sponsor: Mayo Clinic
Recruiting --> Completed Active, not recruiting --> Completed
- Enrollment change: Surveillance Study to Determine the Trends in Acute Hepatitis A Among Panamanian Children (clinicaltrials.gov) - Jan 12, 2012
P=N/A, N=42, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed N=150 --> 42
- |||| Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK
Trial completion: Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) (clinicaltrials.gov) - Jan 12, 2012
P2, N=721, Completed, Sponsor: GlaxoSmithKline
N=150 --> 42 Active, not recruiting --> Completed
- | Trial completion: Surveillance Study to Determine the Trends in Acute Hepatitis A Among Panamanian Children (clinicaltrials.gov) - Jan 12, 2012
P=N/A, N=42, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Recruiting --> Completed
- ||| GS-6620 / Gilead
Trial completion: A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Na (clinicaltrials.gov) - Jan 12, 2012
P1, N=90, Completed, Sponsor: Gilead Sciences
Recruiting --> Completed Active, not recruiting --> Completed
- ||||| ursodeoxycholic acid / Generic mfg.
New P4 trial: Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis (clinicaltrials.gov) - Jan 11, 2012
P4, N=65, Completed, Sponsor: Dr. Falk Pharma GmbH
- | Enrollment open: CONCERVIC: Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients (clinicaltrials.gov) - Jan 11, 2012
P4, N=30, Recruiting, Sponsor: Irmandade Santa Casa de Misericórdia de Porto Alegre
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
New P3 trial, Combination therapy: Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects (clinicaltrials.gov) - Jan 9, 2012
P3, N=0, Available, Sponsor: Janssen-Cilag International NV
- | Olysio (simeprevir) / J&J, Medivir
Trial completion: A Study in Healthy Participants Investigating the Effect of TMC435 on the Pharmacokinetics of Immunosuppressants Cyclosporine and Tacrolimus (clinicaltrials.gov) - Jan 9, 2012
P1, N=29, Completed, Sponsor: Tibotec Pharmaceuticals, Ireland
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||| Olysio (simeprevir) / J&J, Medivir
Trial completion: ASPIRE: A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment (clinicaltrials.gov) - Jan 9, 2012
P2b, N=464, Completed, Sponsor: Tibotec Pharmaceuticals, Ireland
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen, Takeda
New P2 trial: BOS2: Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases (clinicaltrials.gov) - Jan 8, 2012
P2, N=360, Recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
- ||| Daklinza (daclatasvir) / BMS
Enrollment change, Combination therapy: Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care (clinicaltrials.gov) - Jan 4, 2012
P2, N=208, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed N=84 --> 208
- sorafenib / Generic mfg.
New P2 trial: LANEX: Neoadjuvant Sorafenib Therapy Prior to Laser Ablation for Hepatocellular Carcinoma (clinicaltrials.gov) - Jan 4, 2012
P2, N=40, Recruiting, Sponsor: Cardarelli Hospital
- | metadoxine / Generic mfg.
New P2 trial: A Novel Pharmacotherapy for Alcoholism and Alcohol Liver Disease (clinicaltrials.gov) - Jan 3, 2012
P2, N=83, Recruiting, Sponsor: Brown University
- ||||| entecavir / Generic mfg.
Enrollment change, Combination therapy, Monotherapy: Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy in Naive Subjects With Chronic Hepatitis B (clinicaltrials.gov) - Jan 2, 2012
P3, N=669, Completed, Sponsor: Bristol-Myers Squibb
N=84 --> 208 N=384 --> 669
- Enrollment change: A Study to Evaluate the Pharmacokinetics of the Hydrocodone Extended-Release Tablet (CEP-33237) in Subjects With Normal Hepatic Function and Subjects With Moderate Hepatic Impairment (clinicaltrials.gov) - Dec 30, 2011
P1, N=16, Completed, Sponsor: Cephalon
N=384 --> 669 N=24 --> 16
- || saxagliptin / Generic mfg.
Enrollment change: Risk of Acute Liver Failure Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments (clinicaltrials.gov) - Dec 30, 2011
P=N/A, N=113505, Active, not recruiting, Sponsor: Bristol-Myers Squibb
N=24 --> 16 N=180000 --> 113505
- | Trial completion: A Study to Evaluate the Pharmacokinetics of the Hydrocodone Extended-Release Tablet (CEP-33237) in Subjects With Normal Hepatic Function and Subjects With Moderate Hepatic Impairment (clinicaltrials.gov) - Dec 30, 2011
P1, N=16, Completed, Sponsor: Cephalon
N=180000 --> 113505 Recruiting --> Completed
- Trial initiation date: endtxninHE: S. Endotoxin, Inflammatory Mediators and MRS Before and After Treatment in MHE (clinicaltrials.gov) - Dec 28, 2011
P=N/A, N=60, Completed, Sponsor: Govind Ballabh Pant Hospital
Recruiting --> Completed Initiation date: Mar 2010 --> Oct 2011
- sorafenib / Generic mfg.
New P2 trial: Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer (clinicaltrials.gov) - Dec 28, 2011
P2, N=20, Completed, Sponsor: National Cancer Institute (NCI)
- Pegasys (pegylated interferon ? -2a) / Roche
Trial completion: Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous Nonresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4 (clinicaltrials.gov) - Dec 28, 2011
P2/3, N=25, Completed, Sponsor: Sociedad Andaluza de Enfermedades Infecciosas
Initiation date: Mar 2010 --> Oct 2011 Recruiting --> Completed
- | New P4 trial: EPALD: Effect of Probiotics on Gut-Liver Axis of Alcoholic Liver Disease (clinicaltrials.gov) - Dec 26, 2011
P4, N=120, Recruiting, Sponsor: Chuncheon Sacred Heart Hospital
- alisporivir (DEB-025) / Debiopharm, Solid BioSci
New P3 trial, Combination therapy: Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C (clinicaltrials.gov) - Dec 26, 2011
P3, N=6, Terminated, Sponsor: Novartis Pharmaceuticals
- DC Bead (E7040) / Eisai, Boston Scientific
Enrollment open: The LC Bead Trial; Transarterial Chemoembolization of Hepatocellular Carcinoma (HCC)With a Drug-eluting Bead (clinicaltrials.gov) - Dec 22, 2011
P=N/A, N=5, Recruiting, Sponsor: Washington University School of Medicine
Recruiting --> Completed Not yet recruiting --> Recruiting
- dusigitumab (MEDI-573) / AstraZeneca
New P1 trial, Combination therapy, Metastases: MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC. (clinicaltrials.gov) - Dec 22, 2011
P1, N=6, Completed, Sponsor: MedImmune LLC
- ||| Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
New P3 trial: Open-Label, Bridging Study of Telaprevir in Treatment-Na (clinicaltrials.gov) - Dec 21, 2011
P3, N=36, Completed, Sponsor: Janssen-Cilag International NV